IVB108

IVB108 is an adeno-associated virus (AAV)-based gene therapy being developed by InnoVec Biotherapeutics for the treatment of geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD). The therapy is designed for intravitreal administration and utilizes an AAV vector to deliver a genetic payload that expresses an anti-complement agent directly within the ocular environment. This mechanism is intended to inhibit the overactive complement pathway, a key driver of retinal pigment epithelium (RPE) and photoreceptor cell death in GA. By providing sustained, localized expression of the therapeutic protein, IVB108 aims to reduce the treatment burden associated with frequent intravitreal injections of conventional complement inhibitors while slowing the progression of retinal lesions.